Apixaban and dalteparin in active malignancy associated venous thromboembolism

Robert McBane II; Charles L. Loprinzi; Aneel Ashrani; Juliana Perez Botero; Roberto A. Leon Ferre; Stanislav Henkin; Charles J. Lenz; Jennifer G. Le-Rademacher; Waldemar E. Wysokinski

doi:10.1160/TH17-03-0193

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2017; 117(10): 1952-1961
DOI: 10.1160/TH17-03-0193

Trial Protocol Design Paper

Schattauer GmbH

Apixaban and dalteparin in active malignancy associated venous thromboembolism

The ADAM VTE Trial

Authors

Robert McBane II

¹Mayo Clinic, Rochester, Minnesota, USA
Charles L. Loprinzi

¹Mayo Clinic, Rochester, Minnesota, USA
Aneel Ashrani

¹Mayo Clinic, Rochester, Minnesota, USA
Juliana Perez Botero

¹Mayo Clinic, Rochester, Minnesota, USA
Roberto A. Leon Ferre

¹Mayo Clinic, Rochester, Minnesota, USA
Stanislav Henkin

¹Mayo Clinic, Rochester, Minnesota, USA
Charles J. Lenz

¹Mayo Clinic, Rochester, Minnesota, USA
Jennifer G. Le-Rademacher

¹Mayo Clinic, Rochester, Minnesota, USA
Waldemar E. Wysokinski

¹Mayo Clinic, Rochester, Minnesota, USA

Abstract

Summary

Currently, low molecular weight heparin (LMWH) is the guideline endorsed treatment of patients with cancer associated venous thromboembolism (VTE). While apixaban is approved for the treatment of acute VTE, there are limited data supporting its use in cancer patients. The rationale and design of this investigator initiated Phase IV, multicenter, randomized, open label, superiority trial assessing the safety of apixaban versus dalteparin for cancer associated VTE is provided (ADAM-VTE; NCT02585713). The main aim of the ADAM-VTE trial is to test the hypothesis that apixaban is associated with a significantly lower rate of major bleeding compared to dalteparin in the treatment of cancer patients with acute VTE. The primary safety outcome is rate of major bleeding. Secondary efficacy objective is to assess the rates of recurrent VTE or arterial thromboembolism. Cancer patients with acute VTE (n=300) are randomized to receive apixaban (10 mg twice daily for 7 days followed by 5 mg twice daily thereafter) or dalteparin (200 IU/Kg daily for 30 days followed by 150 IU/kg daily thereafter) for 6 months. Stratification factors used for randomization include cancer stage and cancer specific risk of venous thromboembolism using the Khorana score. Participating centers are chosen from the Academic and Community Cancer Research United (ACCRU) consortium comprised of 90 oncology practices in the United States and Canada. Based on the hypothesis to be tested, we anticipate that these trial results will provide evidence supporting apixaban as an effective treatment of cancer associated VTE at lower rates of major bleeding compared to LMWH.

Key words

Cancer - venous thromboembolism - apixaban - dalteparin

Full Text

References

References
1 Prandoni P, Piccioli A, Girolami A. Cancer and venous thromboembolism: an overview. Haematologica 1999; 84: 437-445.
2 Nordstrom M, Lindblad B, Anderson H. et al. Deep venous thrombosis and occult malignancy: an epidemiological study. Br Med J 1994; 308: 891-894.
3 Prandoni P, Lensing AW, Büller HR. et al. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 1992; 327: 1128-1133.
4 Monreal M, Falgá C, Valdés M. et al. Fatal pulmonary embolism and fatal bleeding in cancer patients with venous thromboembolism: findings from the RIETE registry. J Thromb Haemost 2006; 04: 1950-1956.
5 Heit JA, Silverstein MD, Mohr DN. et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 2000; 160: 809-815.
6 Chee CE, Ashrani AA, Marks RS. et al. Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: a population-based cohort study. Blood 2014; 123: 3972-3978.
7 Khorana AA, Francis CW, Culakova E. et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 2007; 05: 632-634.
8 Sorensen HT, Mellemkjaer L, Olsen JH. et al. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000; 343: 1846-1850.
9 Chew HK, Wun T, Harvey D. et al. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 2006; 166: 458-464.
10 McBane RD, Wysokinski WE, Daniels PR. et al. Periprocedural anticoagulation management of patients with venous thromboembolism. Arterioscler Thromb Vasc Biol 2010; 30: 442-448.
11 Ashrani AA, Heit JA. Risk factors for thrombosis in cancer patients. Cancer Treat Res 2009; 148: 95-114.
12 Noble S, Pasi J. Epidemiology and pathophysiology of cancer-associated thrombosis. Br J Cancer 2010; 102 (Suppl. 01) S2-S9.
13 Ashrani AA, Rajkumar SV. Chemotherapy-associated thrombosis. Cancer Treat Res 2009; 148: 181-206.
14 Prandoni P, Trujillo-Santos J, Surico T. et al. Recurrent thromboembolism and major bleeding during oral anticoagulant therapy in patients with solid cancer: findings from the RIETE registry. Haematologica 2008; 93: 1432-1434.
15 Trujillo-Santos J, Nieto JA, Ruíz-Gamietea A. et al. Bleeding complications associated with anticoagulant therapy in patients with cancer. Thromb Res 2010; 125 (02) S58-S61.
16 Tafur AJ, Wysokinski WE, McBane RD. et al. Cancer effect on periprocedural thromboembolism and bleeding in anticoagulated patients. Ann Oncol 2012; 23: 1998-2005.
17 Kearon C, Akl EA, Ornelas J. et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest 2016; 149: 315-352.
18 Lee AYY, Levine MN, Baker RI. et al. Low-Molecular-Weight Heparin versus a Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer. N Engl J Med 2003; 349: 146-153.
19 Lee AY, Rickles FR, Julian JA. et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 2005; 23: 2123-2129.
20 Meyer G, Marjanovic Z, Valcke J. et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 2002; 162: 1729-1735.
21 Deitcher SR, Kessler CM, Merli G. et al. Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl Thromb Hemost 2006; 12: 389-396.
22 Hull RD, Pineo GF, Brant RF. et al. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med 2006; 119: 1062-1072.
23 Lee AY, Kamphuisen PW, Meyer G. et al. Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial. J Am Med Assoc 2015; 314: 677-686.
24 Song Y, Chang M, Suzuki A. et al. Evaluation of Crushed Tablet for Oral Administration and the Effect of Food on Apixaban Pharmacokinetics in Healthy Adults. Clin Ther 2016; 38: 1674-1685.
25 Khorana AA, Kuderer NM, Culakova E. et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008; 111: 4902-4907.
26 Schulman S, Angerås U, Bergqvist D. et al. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost 2010; 08: 202-204.
27 Baron TH, Kamath PS, McBane RD. Management of antithrombotic therapy in patients undergoing invasive procedures. N Engl J Med 2013; 30 (368) 2113-2124.
28 Agnelli G, Buller HR, Cohen A. et al. Oral Apixaban for the Treatment of Acute Venous Thromboembolism. N Engl J Med 2013; 369: 799-808.
29 Einstein Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499-2510.
30 Einstein PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366: 1287-1297.
31 Vedovati MC, Germini F, Agnelli G. et al. Direct oral anticoagulants in patients with VTE and cancer: a systematic review and meta-analysis. Chest 2015; 147: 475-483.
32 Hokusai-VTE Investigators. Büller HR, Décousus H. et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013; 369: 1406-1415.
33 Raskob GE, van Es N, Segers A. et al. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematol 2016; 03: e379-387.
34 Frost C, Song Y, Barrett YC. et al. A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban. Clin Pharmacol 2014; 06: 179-187.
35 https://clinicaltrials.gov/ct2/show/NCT02581176
36 https://clinicaltrials.gov/ct2/show/record/NCT02744092
37 https://clinicaltrials.gov/ct2/show/NCT02583191
38 https://clinicaltrials.gov/ct2/show/NCT02742623
39 van Es N, Di Nisio M, Bleker SM. et al. Edoxaban for treatment of venous thromboembolism in patients with cancer. Rationale and design of the Hokusai VTE-cancer study. Thromb Haemost 2015; 114: 1268-1276.
40 https://clinicaltrials.gov/ct2/show/NCT02555878
41 http://www2.warwick.ac.uk/fac/med/research/hscience/ctu/trials/cancer/select-d/select-d_protocol_v2.0_09-apr-2013.pdf